This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Tandem Diabetes Care, Inc. (TNDM) Soars 6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Hold on to Avanos (AVNS) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Avanos Medical (AVNS) Q1 Earnings, Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) first-quarter 2022 results reflect strength in the Pain Management segment.
Avanos Medical (AVNS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 8.33% and 0.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Abiomed (ABMD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q4 sales.
HCA Healthcare (HCA) Q1 Earnings Miss, Trims '22 EPS View
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter results reflect elevated expenses related to salaries and benefits, partly offset by an uptick in revenues driven by higher patient admissions.
Humana (HUM) Gears Up For Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) first-quarter earnings are likely to reflect the impacts of elevated costs related to investments in technology advancements, partly offset by higher premiums in the Retail segment and sound membership growth.
Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect continued strength across its business segments.
Anthem (ANTM) Q1 Earnings Beat Estimates, Hikes '22 EPS View
by Zacks Equity Research
Anthem's (ANTM) first-quarter results indicate solid top-line growth and strong contribution from each of its businesses, partly offset by higher expenses.
Can Tenet Healthcare (THC) Post Q1 Earnings Beat on Low Costs?
by Zacks Equity Research
Tenet Healthcare's (THC) first-quarter 2022 results are likely to reflect an improvement in adjusted admissions and outpatient admissions.
Is Avanos Medical (AVNS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Avanos Medical (AVNS) and Axcella Health Inc. (AXLA) have performed compared to their sector so far this year.
Philips' (PHG) Lung Suite 3D Imaging Solution Gains Traction
by Zacks Equity Research
Philips' (PHG) innovative lung cancer diagnosis and treatment solution, Philips Lung Suite, is witnessing rapid adoption by clinical partners globally
Philips (PHG) Ties Up With Nuvo Group to Boost Maternal Care
by Zacks Equity Research
Philips (PHG) collaborates with Nuvo to develop maternity care services with digital solutions and eco-system building in rural areas
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
New Strong Buy Stocks for March 11th
by Zacks Equity Research
ABM, AVNS, ASIX, AA, and ESEA have been added to the Zacks Rank #1 (Strong Buy) List on March 11, 2022.
Does Avanos Medical (AVNS) Have the Potential to Rally 26% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Avanos Medical (AVNS) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Avanos Medical (AVNS) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) fourth-quarter 2021 results gain from strength in the chronic care segment.
Avanos Medical (AVNS) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 15% and 1.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for January 24th
by Zacks Equity Research
AGNC, AVNS, and SQ have been added to the Zacks Rank #5 (Strong Sell) List on January 24, 2022
Intuitive Surgical, Inc. (ISRG) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 1.56% and 0.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for January 19th
by Zacks Equity Research
ONEM, ALXO, and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022